Literature DB >> 22996208

Evaluation of an expanded case definition for vaccine-modified measles in a school outbreak in South Korea in 2010.

Young June Choe1, Jae Kyung Hu, Kyung Min Song, Heeyeon Cho, Hee Sook Yoon, Seung Tae Kim, Han Jung Lee, Kisoon Kim, Geun-Ryang Bae, Jong-Koo Lee.   

Abstract

In this study, we have described the clinical characteristics of vaccine-modified measles to assess the performance of an expanded case definition in a school outbreak that occurred in 2010. The sensitivity, specificity, and the positive and negative predictive values were evaluated. Among 74 cases of vaccine-modified measles, 47 (64%) met the original case definition. Fever and rash were observed in 73% (54/74); fever was the most common (96%, 71/74) presenting symptom, and rash was noted in 77% (57/74) of the cases. The original case definition showed an overall sensitivity of 63.5% and a specificity of 100.0%. The expanded case definition combining fever and rash showed a higher sensitivity (72.9%) but a lower specificity (88.2%) than the original. The presence of fever and one or more of cough, coryza, or conjunctivitis scored the highest sensitivity among the combinations of signs and symptoms (77.0%), but scored the lowest specificity (52.9%). The expanded case definition was sensitive in identifying suspected cases of vaccine-modified measles. We suggest using this expanded definition for outbreak investigation in a closed community, and consider further discussions on expanding the case definition of measles for routine surveillance in South Korea.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22996208     DOI: 10.7883/yoken.65.371

Source DB:  PubMed          Journal:  Jpn J Infect Dis        ISSN: 1344-6304            Impact factor:   1.362


  7 in total

1.  Vaccination terminology: A revised glossary of key terms including lay person's definitions.

Authors:  Orlaith C Brennan; John E Moore; Peter J A Moore; Beverley C Millar
Journal:  J Clin Pharm Ther       Date:  2021-08-31       Impact factor: 2.145

Review 2.  Updates on Measles Incidence and Eradication: Emphasis on the Immunological Aspects of Measles Infection.

Authors:  Ali A Rabaan; Abbas Al Mutair; Saad Alhumaid; Mohammed Garout; Roua A Alsubki; Fatimah S Alshahrani; Wadha A Alfouzan; Jeehan H Alestad; Abdullah E Alsaleh; Maha A Al-Mozaini; Thoyaja Koritala; Sultan Alotaibi; Mohamad-Hani Temsah; Ali Akbar; Rafiq Ahmad; Zainab Khalid; Javed Muhammad; Naveed Ahmed
Journal:  Medicina (Kaunas)       Date:  2022-05-20       Impact factor: 2.948

3.  Measles elimination and immunisation: national surveillance trends in Japan, 2008-2015.

Authors:  S Inaida; S Matsuno; F Kobune
Journal:  Epidemiol Infect       Date:  2017-06-23       Impact factor: 4.434

4.  Occurrence of measles in a country with elimination status: Amplifying measles infection in hospitalized children due to imported virus.

Authors:  HyeEun Eom; YoungJoon Park; JooWhee Kim; Jeong-Sun Yang; HaeJi Kang; Kisoon Kim; Byung Chul Chun; Ok Park; Jeong Ik Hong
Journal:  PLoS One       Date:  2018-02-15       Impact factor: 3.240

5.  Measles outbreak in the Philippines: epidemiological and clinical characteristics of hospitalized children, 2016-2019.

Authors:  Fleurette M Domai; Kristal An Agrupis; Su Myat Han; Ana Ria Sayo; Janine S Ramirez; Raphael Nepomuceno; Shuichi Suzuki; Annavi Marie G Villanueva; Eumelia P Salva; Jose Benito Villarama; Koya Ariyoshi; Kim Mulholland; Luigi Palla; Kensuke Takahashi; Chris Smith; Edna Miranda
Journal:  Lancet Reg Health West Pac       Date:  2021-12-15

Review 6.  Measles Elimination Activities in the Western Pacific Region: Experience from the Republic of Korea.

Authors:  Young June Choe; Youngmee Jee; Myoung-don Oh; Jong-Koo Lee
Journal:  J Korean Med Sci       Date:  2015-11-06       Impact factor: 2.153

7.  An Outbreak of Measles in a University in Korea, 2014.

Authors:  Young June Choe; Young Joon Park; Ju Whi Kim; Hye Eun Eom; Ok Park; Myoung Don Oh; Jong Koo Lee
Journal:  J Korean Med Sci       Date:  2017-11       Impact factor: 2.153

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.